GlassScriptPhysician profile
Morgan E Mcdowell
NPI 1801270764
$15,540.09
in general payments reported to CMS, 2019-2025
34 companies · $5,566 in 2025
The $5,566 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $761 · 2022: $1,126 · 2023: $5,379 · 2024: $2,708 · 2025: $5,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,051 · Food and Beverage: $4,798 · Travel and Lodging: $2,898 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,050.50 |
| Food and Beverage | $4,798.03 |
| Travel and Lodging | $2,897.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $907.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $8,680.85 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $2,250.28 | 2023-2025 | Gemtesa, Aptiom, Myfembree |
| Abbvie INC. | $660.73 | 2021-2025 | |
| Abbott Laboratories | $334.92 | 2022-2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $292.80 | 2021-2025 | Ozempic, Wegovy |
| Amgen INC. | $274.92 | 2022-2024 | Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $266.72 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $243.97 | 2021-2024 | Myrbetriq, Veozah |
| C. R. Bard, INC. & Subsidiaries | $183.31 | 2023-2024 | Bard Urinary Drainage Bag |
| Glaxosmithkline, LLC. | $166.65 | 2021-2024 | Arexvy |
| Dexcom, INC. | $164.42 | 2022-2025 | Dexcom G6 Transmitter |
| Rochester Medical Corporation | $137.82 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $123.73 | 2023-2024 | |
| Esperion Therapeutics, INC. | $123.60 | 2021 | |
| Lundbeck LLC | $121.48 | 2025 | Vyepti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $112.53 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.12 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $110.38 | 2025 | Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $109.72 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $104.84 | 2025 | |
| Pfizer INC. | $101.73 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $99.14 | 2021 | |
| Sk Life Science, INC. | $96.24 | 2022 | |
| Argenx US, INC. | $87.73 | 2025 | Vyvgart |
| Medtronic, INC. | $86.37 | 2023 | Interstim |
| Otsuka America Pharmaceutical, INC. | $85.53 | 2023 | Jynarque |
| Myovant Sciences INC. | $79.13 | 2022 | |
| Biogen, INC. | $70.94 | 2023 | |
| Janssen Biotech, INC. | $69.30 | 2025 | Rybrevant, Carvykti |
| Grifols USA, LLC | $58.34 | 2024 | Prolastin-C Liquid |
| Urovant Sciences INC | $49.19 | 2022 | |
| Teleflex LLC | $38.69 | 2023 | Urolift |
| Csl Behring | $25.09 | 2024 | Kcentra |
| E.R. Squibb & Sons, L.L.C. | $17.88 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.